| Abstract |
ABSTRACT
Background: Diabetic peripheral neuropathy (DPN) affects millions worldwide and causes chronic pain, sensory loss, and an increased risk of ulcers and amputations. Controlled trials on cannabis use for DPN are lacking, but studies suggest that high-THC:CBN: CBD (THC=delta-9-Tetrahydrocannabinol, CBN=Cannabinol, CBD=Cannabidiol) transdermal oil improves nervous system function and reduces pain.
Method: A phase III, double-blinded, placebo-controlled, randomized control trial evaluated the efficacy and safety of transdermal medical cannabis in 100 diabetic nerve pain patients at Don Chan Hospital for 12 weeks. Statistical data analysis utilized SPSS Version 28.0 and techniques such as GEE and ANCOVA. The study received ethical approval from Khon Kaen University and the Kalasin Provincial Public Health Office. The trial was registered with the Thai Clinical Trials Registry.
Result: The transdermal medical cannabis (THC: CBN: CBD formula) was found to be significantly effective in reducing painful diabetic peripheral neuropathy at week 12 (B = -7.633, 95% CI = -22.647 to -12.619, p-value = 0.000). The experimental group showed a statistically significant difference in pain relief compared to the control group. THC: CBN: CBD formulas were safe, with 10% of mild adverse skin events reported. No difference was found between the two groups.
Conclusion: The THC: CBN: CBD formula were significantly effective in treating diabetic neuropathy with no significant adverse reactions. Medical professionals may consider it as an alternative for alleviating nerve pain.
|
Publication
Journal Publication
ไทย